Recombinant MPXV A35R protein
Recombinant MPXV A35R protein, which is similar to Vaccinia virus A33R protein, has been created by Sino Biological.
MPXV A35R Protein
A33R protein from the Vaccinia virus is a homolog of MPXV A35R protein. The effective transmission of viral particles from cell-to-cell depends heavily on the A33R protein. It is a possible target for the creation of diagnostic tests, vaccines, and drugs.
Recombinant MPXV A29 protein
Recombinant MPXV A29 protein, which is similar to Vaccinia virus A27 protein, has been created by Sino Biological. A monoclonal antibody that is specific to the monkeypox virus has been found to target the A29 protein.
MPXV A29 protein
Less research has been done on the structure and function of the monkeypox virus A29 protein; however, it is a homolog of the Vaccinia virus A27 protein. The A27 protein serves a variety of purposes:
- Mediate cell fusion by binding heparin on the cell surface;
- IMV trafficking on microtubules and IEV production;
- Anchor for packaging A26 protein into mature viral particles;
- Primary target for neutralizing antibodies.
Recombinant MPXV H3L protein
Recombinant MPXV H3L protein has been created by Sino Biological.
MPXV H3L protein
The MPXV H3L protein is a homolog of the H3L protein of the vaccinia virus. An envelope protein called H3L interacts with heparan sulfate on the surface of cells. It could help the virion connect to the host cell. It is a possible target for the creation of vaccination or drug.
Recombinant MPXV I1L protein
Recombinant MPXV I1L protein has been developed by Sino Biological.
MPXV I1L protein
MPXV I1L protein is Expressed in the late phase of the viral replicative cycle. It is a DNA-binding protein that attaches to the viral telomeric sequence in a hairpin shape.
Recombinant MPXV L1R protein
Recombinant MPXV L1R protein, which is similar to Vaccinia virus J1R protein, has been created by Sino Biological.
MPXV L1R protein
The Vaccinia virus J1R protein has a homolog in the MPXV L1R protein. J1R protein is crucial for viral development, plaque development, and virion morphogenesis.
About Monkeypox virus
Monkeypox virus (MPXV) is a zoonotic enveloped dsDNA virus that can cause monkeypox (MPX). It is a member of the Poxviridae family and belongs to the orthopoxvirus genus.
The monkeypox virus was discovered in lab monkeys for the first time in 1958, and the first human infection with the virus was discovered in 1970. It was believed that West and Central Africa had an endemic human monkeypox viral infection. There were hardly any cases reported from non-endemic nations.
However, the number of cases discovered from May 13–21, 2022, from 12 different nations, has overtaken all instances discovered outside of Africa since 1970.
These cases do not have any confirmed travel connections to an endemic location, unlike earlier outbreaks outside of Africa in the past, such as those in the USA in 2003 and Nigeria in 2017. Scientists are now more aware of this quick spread.
The monkeypox virus has two clades: the West African clade and the Congo Basin clade. The Congo Basin clade is more pathogenic and linked to human-to-human transmission, whereas the West African clade is associated with milder clinical presentation.
Clinical indications of the monkeypox virus infection in humans are comparable to those of smallpox; however, they are milder. Each clade has a mortality rate between 0 and 6% and 8 to 13%. The West African clade was found to be present in cases discovered in May.
In certain scenarios, the smallpox vaccine can guard against MPXV infection. The MPXV infection can be treated with the same antiviral medications used to treat accidental smallpox.
However, as smallpox has been completely eliminated for many years, similar medicines cannot be used extensively to treat monkeypox. More investigation on the monkeypox virus is still required.
About Provir, viral antigen bank
A variety of top-notch recombinant proteins produced in insect and mammalian cells can be found in the Provir™ product line. The quality and bioactivity of these items are extensively examined. More than 1,100 items from 90+ different categories and 380+ different viral strains are part of this exclusive offering.
The main tools used in the study of infectious diseases are recombinant antigens. They are frequently employed in the context of developing antibodies and vaccines. High-quality antigens and antibodies are also essential elements of immunodiagnostic tests.
Featured viral reagents
Influenza virus
SARS-CoV-2
RSV antigens and antibodies